Sorry, you need to enable JavaScript to visit this website.

RELPAX®( eletriptan) How frequently can a patient take RELPAX®?

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.

How frequently can a patient take RELPAX®?

In controlled clinical trials of adult patients (18-65 years of age), single doses of 20 mg, 40 mg and 80 mg were effective for the acute treatment of migraine. A greater proportion of patients had a response following a 40 mg or 80 mg dose than following a 20 mg dose. The recommended initial dose is 40 mg. The maximum single dose is 80 mg.

If the initial dose is ineffective, controlled clinical trials have not shown a benefit of a second dose to treat the same attack. However, if the headache returns following initial improvement, there is evidence to suggest that a repeat dose may be beneficial. If a second dose is required, it should not be taken within 2 hours of the initial dose.

The maximum daily dose should not exceed 160 mg. No information is available on the maximum weekly or monthly usage of Relpax.

Excessive use of any anti-migraine medicinal product can lead to daily chronic headaches.

Many experts limit acute therapy to two headache days per week on a regular basis. The German Migraine and Headache Society (DMKG) guideline recommends that triptans are not to be used more than ten days per month, and/or more than on 3 consecutive days. Various other guidelines on the management of migraine have been published.


1. Relpax®(eletriptan hydrobromide) Product Information

2. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-62.

3. DMKG Therapy recommendations available at

4. Olesen J, Bousser MG, Diener HC, et al on behalf of the International Headache Society. The International Classification of Headache Disorders, 3rd Edition (beta version) of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2013;33(9):733-5.

5. British Association for the Study of Headache (BASH) Management Guidelines 2010. Available at

6. Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES) Chronic Daily Headache Guidelines 2004. Available at

Tips and Tricks

Searching Tips
For more accurate search results, please ensure you enter at least two specific keywords
Haven't found what you are looking for?
Try entering additional or different clinical terms to refine your search. Or you can submit an enquiry online via the Send Medical Enquiry tab or contact Pfizer’s Medical Information Service on 1800 675 229.
Product Information
For a full list of Product Information documents, click on the Product Information tab.
Want to provide some feedback?
Complete the Pfizer Medical Information Website Survey to answer a few questions about your experience and satisfaction with the site.

Contact Pfizer Medical Information

Speak live with a Pfizer Medical Information professional
1800 675 229
Monday to Friday 9am – 5pm EST